Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma

RARITAN, N.J., Jan. 27, 2023. The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials